Apellis Pharmaceuticals, Inc. (BIT:1APLS)

Apellis Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	1,004	781.37	396.59	75.42	66.56
Revenue Growth (YoY)	28.46%	97.02%	425.83%	13.31%	-73.44%
Cost of Revenue	102.24	117.72	58.51	5.64	0.2
Gross Profit	901.55	663.64	338.08	69.79	66.36
Selling, General & Admin	550.27	501.05	500.82	277.16	176.77
Research & Development	295.85	327.57	354.39	387.24	345.87
Other Operating Expenses	-	-	-	-	80
Operating Income	55.43	-164.98	-517.12	-594.61	-536.28
Interest Income	13.14	12.77	20.93	8.91	0.42
Interest Expense	-44.33	-40.39	-29.58	-32.63	-13.24
Other Non-Operating Income (Expense)	-0.13	-4.12	-0.73	-33.18	-196.9
Total Non-Operating Income (Expense)	-31.32	-31.74	-9.38	-56.89	-209.73
Pretax Income	24.11	-196.72	-526.5	-651.5	-746
Provision for Income Taxes	1.72	1.16	2.13	0.67	0.35
Net Income	22.39	-197.88	-528.63	-652.17	-746.35
Net Income to Common	22.39	-197.88	-528.63	-652.17	-746.35
Shares Outstanding (Basic)	126	124	119	106	84
Shares Outstanding (Diluted)	130	124	119	106	84
Shares Change (YoY)	4.80%	4.40%	11.84%	25.70%	12.32%
EPS (Basic)	0.18	-1.60	-4.45	-6.15	-8.84
EPS (Diluted)	0.20	-1.60	-4.45	-6.15	-8.84
Free Cash Flow	45.01	-88.27	-595.51	-515.27	-564.23
Free Cash Flow Per Share	0.35	-0.71	-5.02	-4.86	-6.68
Gross Margin	89.81%	84.93%	85.25%	92.53%	99.70%
Operating Margin	5.52%	-21.11%	-130.39%	-788.38%	-805.67%
Profit Margin	2.23%	-25.32%	-133.29%	-864.70%	-1121.27%
FCF Margin	4.48%	-11.30%	-150.16%	-683.18%	-847.66%
EBITDA	56.99	-163.18	-515.34	-593.06	-534.79
EBITDA Margin	5.68%	-20.88%	-129.94%	-786.32%	-803.43%
EBIT	55.43	-164.98	-517.12	-594.61	-536.28
EBIT Margin	5.52%	-21.11%	-130.39%	-788.38%	-805.67%
Effective Tax Rate	7.14%	-0.59%	-0.40%	-0.10%	-0.05%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.